Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2023 and 2024.
-
Tight liquidity NBB
Cash and receivables cover 24 % of short-term debt in 2024; threshold 65 %.
-
Shrinking team NBB
FTE fell two years in a row, from 3.3 to 2.
-
Busy address KBO
34 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2024
BIOCYTE BENELUX from Sint-Lambrechts-Woluwe, company number BE0730898265, closed financial year 2024 with a result of € -999 after tax. For that financial year BIOCYTE BENELUX recorded a gross margin of € 156,242 and equity of € -212,649. Compared with financial year 2023, the result moved from € -89,476 to € -999. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on September 19, 2025.
€ -212,649
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -999
▲ 99 % less loss than in 2023
Profit after tax over the fiscal year.
€ 46,272
▲ 17% vs 2023
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -232,649.
People and assets in 2024
2
▼ 0.9 vs 2023
Average over the fiscal year, from the social balance sheet.
€ 138,099
▼ 53% vs 2023
€ 69,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 634
▼ 66% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2024
None
No bank loans on the last day of the fiscal year.
€ 301,692
▲ 11% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 22,062
▼ 81% vs 2023
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Gross margin | € 127,684 | € 233,439 | € 220,738 | € 156,242 | ▼ 29% |
| Profit after taxes | € -50,288 | € -73,843 | € -89,476 | € -999 | ▲ € 88,477 |
| Equity | € -48,331 | € -122,174 | € -211,650 | € -212,649 | |
| Total debts | € 224,883 | € 409,518 | € 451,625 | € 361,023 | ▼ 20% |
| Cash | € 41,334 | € 24,539 | € 39,657 | € 46,272 | ▲ 17% |
| Retained profit | € -68,331 | € -142,174 | € -231,650 | € -232,649 | |
| Balance sheet total | € 176,552 | € 287,344 | € 239,975 | € 148,374 | ▼ 38% |
| Employees (FTE) | 2.6 | 3.3 | 2.9 | 2 | ▼ 0.9 |
Key figures of BIOCYTE BENELUX, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to BIOCYTE BENELUX?
What happened at BIOCYTE BENELUX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: loss of € 999. filed late Source: NBB ↗
- Benjamin Francq became a director. NBB
- Bon Topco SAS became a director. NBB
- New establishment in Sint-Lambrechts-Woluwe. KBO
- Start of the company according to the CBE. KBO
In short
From € 50,288 loss in 2021 to € 999 loss in 2024.
Paid € 1,774 in corporate taxes since 2021.
On average € 78,100 of value added per employee in 2024.
A new publication or filing at BIOCYTE BENELUX? We notify you, reason included.
Follow BIOCYTE BENELUXDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of ixX pharma comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
BIOCYTE BENELUXBehind BIOCYTE BENELUX are Benjamin Francq and Bon Topco SAS. The shares are held by ixX pharma (100%).
Directors
According to the 2024 annual accounts
Benjamin Francq
Director
since 2024
Director · represented by Nicolas Brodetsky
Also active at: Laboratoire Densmore Belgium, PONROY VITARMONYL BENELUX
since 2023
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Veldkapelgaarde 30 box 1.30.30
1200 Sint-Lambrechts-Woluwe
Veldkapelgaarde 30
1200 Sint-Lambrechts-Woluwe
Active since 19 July 2019
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 34 companies are registered at this address.
All companies at this address →Centre de Sante Universitaire de la Faculte de Medecine de l'Universite Catholique de Louvain (Section francophone)
€ 28,963 revenue · 2024
Services de Santé Mentale de l'UCL à Bruxelles
€ 704 revenue · 2024
Belgische Vereniging voor Medische, Informatica - Société belge d'Informatique médicale
Centre universitaire d'information sur les Professions médicales et-ou paramédicales
European Society of Surgical Oncology
€ 1.2 million revenue · 2025
+29 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0730.898.265
- VAT number
- BE 0730.898.265
- Registered office
- Veldkapelgaarde 30 bus 1.30.30, 1200 Sint-Lambrechts-Woluwe
- Names & denominations
- BIOCYTE BENELUX
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 19 July 2019
- Peppol
- Active · Active since 30 Jul 2025
- Activities · NACE
Groothandel in parfumerieën en cosmetica
Handelsbemiddeling in de niet-gespecialiseerde groothandel
Vervaardiging van andere voedingsmiddelen, neg
Groothandel in andere voedingsmiddelen, neg